Search

Adding elotuzumab to standard treatment for multiple myeloma significantly reduced the risk of disease progression, with benefits sustained at two years

ELOQUENT-2, which evaluated elotuzumab in combination with lenalidomide and dexamethasone, is the first Phase III study to demonstrate the benefit of directly activating the immune system in the treatment of patients with relapsed or refractory multiple myeloma.

Read more

Meet Shaun McCann, our July volunteer of the month

Can you tell us what you do for EHA and when you started?
I have been a member of the EHA since its beginning. I began taking part in tutorials in 2007.

Read more

Meet Shaun McCann, our July volunteer of the month

Can you tell us what you do for EHA and when you started?
I have been a member of the EHA since its beginning. I began taking part in tutorials in 2007.

Read more

CME-European Accreditors: A New European CME/CPD Association

A new association of accrediting boards in Continuing Medical Education/Continuing Professional Development in Europe has been established.

Read more

EHA and EMBL-EBI are launching CBTH

The Hague, May 2022 - The European Hematology Association (EHA) and the EMBL’s European Bioinformatics Institute (EMBL-EBI) are launching a new mentoring program, Computational Biology Training in Hematology (CBTH), this June.

Read more

EHA collaborates with THD to provide critical aid to hematologists

The Hague (Netherlands), June 23, 2023. The European Hematology Association (EHA) is proud to announce its partnership with the Türk Hematoloji Derneği (THD) in a joint effort to support hematologists working in earthquake-affected areas in Türkiye and Syria.

Read more

SWG Educational Activities

SWG meeting, EHA2023 CongressGuidelines SessionSession title‘The European Guidelines on Diagnosis and Management of Neutropenia in Adults and Children.

Read more